Researchers at the National Cancer Institute (NCI) seek licensing for an improved cell line called Tni-FNL which is capable of high level expression of heterologous proteins using baculovirus expression systems.
The National Cancer Institute's Cancer and Inflammation Program is seeking statements of capability or interest from parties interested in licensing therapeutic agents that generate Nitroxyl (HNO) in physiological media.
The Laboratory of Cardiovascular Science at the National Institute on Aging, is seeking parties interested in collaborative research to further co-develop a potential new hypertensive drug based on recombinant human erythropoietin (rhEPO).
Researchers at the National Cancer Institute (NCI) have developed an engineered storage unit for frozen tissue, that provides a permanent base on which to mount tissue frozen in OCT and an enclosure for storage. The unit provides for chain-of-custody labeling and acts as an insulating container to protect the specimen. Other elements include devices for freezing the tissue to the base, as well as a holder for the base to facilitate cryosectioning. Application of the storage system allows a frozen tissue specimen to be moved between storage and cryosectioning without loss of label, deformation of tissue, or thermal alterations.
Researchers at the National Cancer Institute (NCI) developed a genetic assay for detecting transcription errors in RNA synthesis. This new assay extends the familiar concept of an Ames test which monitors DNA damage and synthesis errors to the previously inaccessible issue of RNA synthesis fidelity. The FDA requires genetic DNA focused tests for all drug approval as it assesses the in vivo mutagenic and carcinogenic potential of a drug. The new assay will open an approach to monitoring the impact of treatments on the accuracy of RNA synthesis. Errors in transcription have been hypothesized to be a component of aging and age-related diseases. The National Cancer Institute (NCI) seeks licensing partners for the genetic assay.
Recombinant human tissue inhibitors of metalloproteinases (rhTIMP-2) have been shown to suppress tumor growth and tumor-associated angiogenesis. NCI Radiation Oncology Branch (ROB) researchers have developed a unique HEK-293F cell line which stably expresses rhTIMP-2, increasing the production of TIMP-2 to quantities sufficient to be used for testing and development as a therapeutic for various cancers, ischemic diseases (myocardial infarct and cerebrovascular infarct), and neurodegenerative diseases.
Researchers at the National Cancer Institute (NCI) RNA Biology Laboratory have developed nanoparticles that can deliver an agent (i.e., therapeutic or imaging) and release the agent upon targeted photoactivation allowing for controlled temporal and localized release of the agent.
Researchers at the National Institute on Drug Abuse (NIDA) have developed an apparatus that is used to image rodents while they are awake. The biological effects of agents on the rats can be imaged (via MRI for instance) in real time over a prolonged period of time.
The National Cancer Institute (NCI) seeks research licensees for a process that reduces nucleic acid (RNA and DNA) degradation and improves protein integrity in tissue preserved as fixed paraffin embedded specimens.
Researchers at the National Institute of Health (NIH) and National Institute of Standards and Technology (NIST) seek licensing or co-development partners for a method to predict functions, identity, disease state, and health of stem cells using machine learning.
The National Institutes of Health, through The National Institutes of Health - Clinical Center (NIH-CC) and the National Heart Lung and Blood Institute (NHLBI), seeks licensing and/or co-development partners for a nitric oxide cream for the treatment of ulcers associated with sickle cell disease.
The National Institute of Health - Clinical Center (NIH-CC) seeks licensing and/or co-development of a system and method for tracking eye movement to increase the efficacy of visual diagnoses by radiologists.
The National Institutes of Health - Clinical Center (NIH-CC) seeks to license and/or co-develop methods of reading chest x-rays using a deep learning models to detect a disease and describe its contents.
The National Cancer Institute (NCI) seeks research co-development opportunities and/or licensees for a new biomedical device for biopsy tissue collection and storage in a sterile, well-defined environment.
The National Cancer Institute (NCI) seeks licensing partners for a novel modified insect cell line, Sf9-ET, that can quickly and efficiently determine baculovirus titers during the expression of recombinant proteins from a baculovirus-based protein expression system.
The National Eye Institute (NEI) seeks research co-development or licensees for making research- or clinical-grade preservation solutions for cold-sensitive organ transplantation or protection of brain injury or trauma during surgery.